Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 3 31Phase 1/2 28Phase 1 20Phase 2/3 3Phase 4 2

Status

Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Liver Neoplasms 1Carcinoma, Hepatocellular 1Advanced Non-small Cell Lung Cancer 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × lenvatinib × Clear all
NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07177716 2025-09-17

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

L & L Bio Co., Ltd., Ningbo, China

Phase 2/3 Not yet recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2/3 Terminated
16 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡